# Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

Study · id `cardio:ct-nct04135287` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04135287](<https://clinicaltrials.gov/study/NCT04135287>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04135287

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 315 participants.

## Technical summary

Registry record NCT04135287. Allocation not applicable; no masking; primary purpose treatment. Start 2020-03-01 (actual); primary completion 2023-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 315 participants (planned count; ClinicalTrials.gov record NCT04135287, source copy `cardio:ctgov-nct04135287-2020-07-21`, retrieved 2026-10-26)
- Started: 2020-03-01 (actual) (ClinicalTrials.gov record NCT04135287, source copy `cardio:ctgov-nct04135287-2020-07-21`, retrieved 2026-10-26)
- Primary completion: 2023-03-01 (anticipated) (ClinicalTrials.gov record NCT04135287, source copy `cardio:ctgov-nct04135287-2020-07-21`, retrieved 2026-10-26)
- Completion: 2023-07-15 (anticipated) (ClinicalTrials.gov record NCT04135287, source copy `cardio:ctgov-nct04135287-2020-07-21`, retrieved 2026-10-26)
- Countries: Kuwait (ClinicalTrials.gov record NCT04135287, source copy `cardio:ctgov-nct04135287-2020-07-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04135287-2020-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): GLP-1 receptor agonist
- Lead sponsor: Dasman Diabetes Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: fbea3c5c87ac8e14b15ea3efe5d95a77fba34de7d6db3038321f97ed889d66a1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
